November 22, 2024

bladder cancer

First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations TAR-210 Phase 1 Study Results
2 min read

First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from an open-label, multicenter...
Read More
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial Astellas Pharma and Seagen Logos
2 min read

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) and Seagen Inc. (Nasdaq: SGEN) today announced...
Read More

You may have missed

Lupin’s Humrahi Expands to Heart Health
2 min read

Lupin’s Humrahi Expands to Heart Health

November 20, 2024
Boston Scientific Launches AVVIGO™+ Multi-Modality Guidance System in India
2 min read

Boston Scientific Launches AVVIGO™+ Multi-Modality Guidance System in India

November 13, 2024
KW Delhi-6 Mall Joined Hands with Yashoda Healthcare to Spread Awareness on Breast Cancer
2 min read

KW Delhi-6 Mall Joined Hands with Yashoda Healthcare to Spread Awareness on Breast Cancer

November 7, 2024
India’s reputation as the “Pharmacy to the World” is Potentially Under Threat Substandard Imports of IPA add to the Quality Burden
3 min read

India’s reputation as the “Pharmacy to the World” is Potentially Under Threat Substandard Imports of IPA add to the Quality Burden

September 25, 2024